Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Spekulatius who wrote (3276)	4/2/2001 2:41:14 AM
From: Miljenko Zuanic	Respond to of 52153

<<I believe that these macrotrends will favor the bigger, cash rich biotechs : VRTX, MLNM, HGSI, ABGX, MEDX, PRCS which will streamline and industrialize their methods.>> The real problem is that large cash reach bios may start to think like pharma. "We are best, self-sufficient, fast growing, technology advance,...BS.. company." IMW, they are open to macrotrends as well. AMGN, BGEN and now IMNX experience speak for itself. MLNM was smart to form two large 50-50 deal, where technology advance from both partners will be shared and combined. VRTX done similarly with Novartis deal. What is wrong if you combine, for instance, MLNM-VRTX, HGSI-INCY, MEDX-ABGX, PRCS-ALXN,...so many options, so little fait! Miljenko

To: Spekulatius who wrote (3276)	4/2/2001 11:06:16 AM
From: scaram(o)uche	Read Replies (4) \| Respond to of 52153

OK, let's pick some business plans that would/could be in trouble, given these worries/scenarios/whatever. TELK...... poorly-timed IPO didn't raise the funds anticipated or necessary to support plans. They're stating that they plan to take 289 forward alone. They don't have the cash to do such, but they're not going to run out soon. There's no near-term crunch. Phase II trials just initiated, research premium of about $85 million. What should they do? Should MLNM buy them (stock deal)? CRGN..... leverage...... a target discovery machine, trying to transition to a biologicals powerhouse. No pipeline to complement the massive stash of cash. What should they do? Who should they merge with? NPSP...... is the significant pile of cash sufficient? Are there any blockbusters in the broad pipe, something that says that the first merger/buyout/whateverbiowaandHarrywanttocallit will be sufficient? Should they just sit it out and pray? Other examples where answers might provide sector CEOs with a clue? Any answers to the questions asked?